Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2016-11-10 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (1830 characters) from the Israel Securities Authority that explicitly states 'Attached hereto is a report on Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA). 9M 2016
2016-11-10 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the FDA has accepted the Biologics License Application (BLA) for a human rabies immunoglobulin therapy developed by Kedrion Biopharma and Kamada. It discusses clinical trial results, market potential, and regulatory timelines (PDUFA goal date). This type of announcement, focusing on a specific regulatory milestone (BLA acceptance) and providing key business/product updates outside of routine financial reporting (like 10-K or quarterly results), fits best under the general category of corporate news or regulatory updates. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific transaction (CAP, TAR), and it is a formal announcement, it aligns most closely with a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is a product development milestone announcement. Given the options, RNS serves as the best general regulatory/corporate announcement fallback when a more specific code like 'CAP' (financing) or 'LTR' (legal) does not apply. It is not an ER because it is not primarily focused on financial results for a period, but rather on FDA acceptance.
2016-11-07 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 07/11/2016. It explicitly states that it is reporting on an event and attaches a PDF file titled 'Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment'. Since the document itself is a brief announcement whose primary function is to notify the market that a specific report/news item is available (the attached PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K, IR) or a transcript (CT).
2016-11-07 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a press release dated November 2, 2016, announcing a clinical plan for a Phase 2/3 trial for Alpha-1 Antitrypsin (G1-AAT IV) for Graft-Versus-Host Disease (GvHD). It details the trial design, endpoints, collaboration with Shire, and includes standard 'About' and 'Forward-Looking Statements' sections typical of corporate news releases. This content is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial announcement like a dividend notice or insider trade. It is an announcement of clinical/development progress, which often falls under general investor relations material. Since it is a detailed announcement about clinical development and partnership milestones, it is best classified as an Investor Presentation (IP) if it were a slide deck, but as a press release detailing operational/clinical news, it most closely aligns with a general Investor Relations announcement. Given the provided categories, and since it is not a formal financial report, a specific regulatory form, or a transcript, the most appropriate category for a detailed operational/clinical update press release that is not explicitly an Earnings Release (ER) is often the general Regulatory Filings (RNS) as a fallback, or potentially Investor Presentation (IP) if it were structured as a presentation. However, based on the content being a news announcement about clinical trial initiation and progress, it functions as a key piece of investor information. Since it is a detailed announcement of operational/clinical progress rather than a formal financial report, and it doesn't fit the other specific categories, RNS (Regulatory Filings/General Announcement) is the safest fallback, although IP might capture the intent if the content were more strategic/forward-looking presentation style. Given the structure is a standard press release announcing a major clinical step, RNS is the most suitable catch-all for non-standard, yet important, corporate news.
2016-11-02 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 02/11/2016. The key content states: 'Attached hereto is a report on *Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease*'. Since the document itself is short (1857 chars) and its primary function is to announce the publication of an attached report (a PDF file), it fits the definition of a Report Publication Announcement (RPA). It is not the full clinical trial report itself, but the notification of its release.
2016-11-02 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed by a "Foreign Private Issuer" with the SEC. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country, or that is otherwise material to investors. The content is a "News Release" announcing the extension of a supply and distribution agreement, which is material non-public information. While it contains financial details, it is not a comprehensive periodic report (like 10-K or IR). Since Form 6-K is a general reporting requirement for foreign issuers and the content is a specific announcement (a news release), it falls best under the general category for miscellaneous regulatory filings that don't fit the specific US-centric forms or report types listed. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a mandatory SEC filing that serves as a vehicle for disseminating material news.
2016-10-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.